Between January and September 2018, Russia imported 68.9 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 26.8% higher than that of the same period of 2017. In physical terms, the dynamics are -8.5%, and the imported volume is 8,300 tons.

By the end of the period, the dynamics of the import of both pharmacopoeial and technical APIs have nearly become equal, with +26.9% and +23.9%, respectively. However, the dynamics of the technical API import in physical terms is decreasing, while being ahead of the average market dynamics (-14.5%.)

Between January and September 2018, 17 new companies entered the list of the companies importing pharmacopoeial APIs to Russia, while the number of the new companies for the technical API import list is only 2. The total number of the companies importing pharmacopoeial and technical APIs to Russia are 474 and 89, respectively. The product list for pharmacopoeial APIs included 28 new names out of 625, while that for technical APIs lost 22 names out of 115.

Despite the technical API import volumes falling, there are positive moments. Indian Arene Lifesciences is the absolute leader, with nearly 32% of the total technical API import in monetary terms. In 2018, it imported three products to Russia. Pharmasyntez is their only consumer, anti-HIV generics Simanod (Atazanavir) and Calidavir (Lopinavir+Ritonavir) are produced on its facilities in Irkutsk.

Dynamics of pharmacopoeial and technical API import to Russia, customs clearance prices (2015 – 2017, January – September 2018), bln RUB